[Metabolic support of the ischemic heart during cardiac surgery].
We examine [IBM1] the basic principles and clinical results of the metabolic intervention with glucose-insulin-potassium (GIK) solutions in the field of cardiovascular surgery. On the basis of many international publications concerning this subject, and the experience obtained in the operating room of the Instituto Nacional de Cardiologia "Ignacio Chávez", we conclude that the metabolic support wit GIK is a powerful system that provides very useful energy to protect the myocardium during cardiac and non-cardiac surgery. The most recent publications indicate their effects in reducing low output syndromes, due to interventions on the coronary arteries, as well as producing a significant reduction of circulating fatty acids. These effects are produced also in the field of interventional cardiology, where GIK solutions protect the myocardium against damage due to impaired microcirculation. It is evident that these solutions must be utilized in higher concentrations that the initial ones, equal to those employed in laboratory animals. On the other side, it is worthy to remember that it has been always underlined that this treatment represents only a protection for the myocardium. Therefore, its association with other drugs or treatments favoring a good myocardial performance is not contraindicated--on the contrary, it yields better results. The present review presents pharmacological approaches, such as the use of glutamato, aspartate, piruvato, trimetazidina ranolazine and taurine to optimize cardiac energy metabolism, for the management of ischemic heart disease.
Luna Ortiz
Pastor
P
Departamento de Anestesia, Instituto Nacional de Cardiología "lgnacio Chávez", México, D.F. pluna98@yahoo.com
Serrano Valdés
Xenia
X
Rojas Pérez
Eduardo
E
de Micheli
Alfredo
A
D006348:Cardiac Surgical Procedures; D003326:Coronary Circulation; D004734:Energy Metabolism; D005227:Fatty Acids / Q000097:blood; D005947:Glucose / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D008833:Microcirculation; D017202:Myocardial Ischemia / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism*; D011188:Potassium / Q000008:administration & dosage / Q000627:therapeutic use
D005227:Fatty Acids; D007328:Insulin; C030396:glucose-insulin-potassium cardioplegic solution; D005947:Glucose; D011188:Potassium